ERBB2 and neoplasm: Furthermore, this finding rules out the possibility that the changes in IFN-γ levels engendered by CT26/HER2 cells might increase the expression of non-cognate MHC class I molecules on tumor cells, thus leading to the inhibition of tumor recognition by Ag-specific CTLs.